ELAN, DINO and EMBC made it to the Zacks Rank #1 (Strong Buy) value stocks list on October 6, 2025.
Zacks·19d ago
More News
Best Income Stocks to Buy for September 15th
CZNC, EMBC and FFBC made it to the Zacks Rank #1 (Strong Buy) income stocks list on September 15, 2025.
Zacks·1mo ago
New Strong Buy Stocks for September 15th
RNGR, LRN, BWA, KT and EMBC have been added to the Zacks Rank #1 (Strong Buy) List on September 15, 2025.
Zacks·1mo ago
Best Value Stocks to Buy for September 9th
JXN, EMBC and KT made it to the Zacks Rank #1 (Strong Buy) value stocks list on September 9, 2025.
Zacks·2mo ago
Embecta Corp. (EMBC) Crossed Above the 200-Day Moving Average: What That Means for Investors
Good things could be on the horizon when a stock surpasses the 200-day simple moving average. How should investors react?
Zacks·2mo ago
Wall Street Analysts Predict a 25.69% Upside in Embecta Corp. (EMBC): Here's What You Should Know
The consensus price target hints at a 25.7% upside potential for Embecta Corp. (EMBC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks·2mo ago
Solventum (SOLV) Tops Q1 Earnings and Revenue Estimates
chainwire·6mo ago
Embecta Corp. Tops Q3 Earnings and Revenue Estimates
Embecta Corp. (NASDAQ: EMBC) came out with quarterly earnings of $0.74 per share, beating the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.69 per share a year ago...
Benzinga·1y ago
Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company
Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company Genpact Supports embecta's Spin-Off into an Independent Diabetes Care Company PR Newswire NEW YORK, July 29, 2024...
PR Newswire·1y ago
Insulin Device Maker Embecta Weighs Sale After 70% Share Decline Following Becton Dickinson Spin-Off
Embecta is exploring a potential sale after a nearly 70% drop in share price since its spin-off from Becton Dickinson. The company's U.S. business has struggled with the rise of GLP-1 drugs and...